Andreas Reichel PhD

Andreas is Vice President and Head of Research Pharmacokinetics at Bayer Pharma Drug Discovery. His department has two sites (Berlin and Wuppertal) and is responsible for the DMPK and bioanalytics support of drug discovery projects of all therapeutic areas of the portfolio including cardiology, oncology, hematology, gynaecological therapy, and ophthalmology. Andreas received his PhD in Cell Biology from the University of Leipzig in 1994 studying the regulation of nutrient transport processes at the blood-brain barrier (BBB) in vivo under the supervision of Prof. Armin Ermisch.

Between 1994 and 1997 he was working in the laboratories of Profs. Joan Abbott and David Begley, King’s College London, where he became interested in in vitro models of the BBB. Funded by several pharmaceutical companies he started working on approaches to assess and predict the CNS penetration of drugs. In 1997, Andreas joined Discovery DMPK at Hoffmann-La Roche, Basel, where he expanded his area of expertise to intestinal and hepatic transport processes and their relevance to drug absorption, drug disposition and drug-induced liver toxicity.